Artiva Biotherapeutics, Inc. (ARTV) Stock Statistics & Valuation Metrics

Artiva Biotherapeutics, Inc. has a market cap or net worth of $87.69M. The enterprise value is -$92.33M.

Artiva Biotherapeutics, Inc. has 24,425,762 shares outstanding. The number of shares has decreased by -2.65% in one year.

Artiva Biotherapeutics, Inc.’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -32.85%.

The current PE Ratio of Artiva Biotherapeutics, Inc. is ―. Artiva Biotherapeutics, Inc.’s PEG ratio is -0.01.

In the last 12 months, Artiva Biotherapeutics, Inc. had revenue of 251.00K and earned -58.49M in profits. Earnings per share was -5.20.

In the last 12 months, operating cash flow was -76.67M and capital expenditures -2.23M, giving a free cash flow of -78.91M billion.

Artiva Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Artiva Biotherapeutics, Inc. upcoming earnings date is Mar 30, 2026, After Close (Confirmed).

Artiva Biotherapeutics, Inc. as a current ratio of 15.39, with Debt / Equity ratio of 9.05%

In the past 12 months, Artiva Biotherapeutics, Inc. has paid 0.00 in taxes.

Artiva Biotherapeutics, Inc. EV to EBITDA ratio is -3.39, with an EV/FCF ratio of -3.95.

Artiva Biotherapeutics, Inc. has $122.97M in cash and marketable securities with $11.69M in debt, giving a net cash position of $111.28M billion.

Gross margin is 0.00%, with operating margin of -26805.58%, and net profit margin of -23303.98%.

The average price target for Artiva Biotherapeutics, Inc. is $16.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy